Most significant positive evidence
The dominant evidence concerns a safe and effective vaccine that prevented paralysis and death on a vast scale, together with institution-building for future biomedical research.
Person
Jonas Salk
The assessment covers development of the first successful inactivated polio vaccine, participation in large clinical trials and creation of a collaborative nonprofit research institute.
This is a contemporary assessment current to 26 June 2026. It must be revised as later conduct and evidence become available.
Ethical assessment categories
Current published result
Overall ethical score
+91.40
Reasoned summary
Salk’s scientific leadership produced an intervention of extraordinary public benefit and helped establish a durable research institution. Properly recognising collaborators still leaves a strongly positive personal record.
This assessment presents six separate ethical dimensions rather than one overall moral score. Each result must be read with its evidence, plausible range, confidence, disputes, exclusions, severe-harm findings and sources.
Most significant negative evidence
The score is moderated by the collective nature of vaccine science, ethical questions inherent in mid-century mass trials and the risk of overstating any one scientist’s sole contribution.
Read the full Jonas Salk ethical assessment, evidence and sources
Six-dimensional ethical profile
The overall figure is the equal-weight average of the applicable dimensions. It does not replace the separate scores, evidence or uncertainty.
- Personal moral conduct
- +94.00
- Rights and dignity
- +87.03
- Nonviolence and harm
- +84.00
- Stewardship of power
- +95.00
- Wisdom and truthfulness
- +93.49
- Consequential legacy
- +94.89
- Severe-harm record
- No separate finding recorded
Assessment history
Ethical assessment: Jonas Salk (1941–1995)
1941–1995 · Published assessment · reviewed June 26, 2026
Result: Six-dimensional ethical profile